The New Molecules Are Changing the Course of Pediatric Chronically Active Ulcerative Colitis: A Series of Pediatric...

Area of Science:

• Pediatric Gastroenterology
• Inflammatory Bowel Disease Research
• Novel Therapeutics in UC

Background:

• Chronically active ulcerative colitis (UC) presents management challenges, especially with evolving treatment landscapes.
• Decreased colectomy experience contrasts with increased medical therapeutic options for UC.
• Patients with chronically active UC often require extended management to identify effective treatments.

Purpose of the Study:

• To report successful treatment of refractory pediatric ulcerative colitis (UC) using advanced biologics.
• To highlight the efficacy of ustekinumab and tofacitinib in pediatric UC cases.
• To emphasize the role of patient-family collaboration in treatment decision-making for pediatric UC.

Main Methods:

• Case report of two pediatric patients with chronically active UC.
• Documented lack of response to intravenous steroids and sequential therapies.
• Administration of ustekinumab and tofacitinib as rescue therapies.

Main Results:

• Both pediatric patients achieved clinical remission following treatment with ustekinumab and tofacitinib.
• These advanced therapies, though more established in adults, showed efficacy in pediatric UC.
• Multidisciplinary management and close follow-up were integral to treatment success.

Conclusions:

• Ustekinumab and tofacitinib represent viable therapeutic options for refractory pediatric ulcerative colitis (UC).
• Active patient and family participation significantly aids medical decision-making and treatment adherence.
• Successful medical management with these agents can potentially avert the need for colectomy in pediatric UC.